A Feasibility Study of the Optune Electric Field Device to

Full Title PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma Purpose The purpose of this study is to evaluate the safety and effectiveness of the Optune device for treating children with supratentorial high-grade gliomas and ependymomas that have come back or continued to grow despite prior treatment

Request A Quotation!

Neurology Neurological Sciences Clinical Trials

PBTC-048 Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma PBTC-049 A Phase I Study of Savolitinib in Recurrent Progressive or Refractory Primary CNS Tumors PBTC-050 A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors PBTC-051 Phase I

Request A Quotation!

Full Schedule

Moderator: Glenn J Lesser – Wake Forest Baptist Medical Center Moderator: W K Alfred Yung – University of Texas MD Anderson Cancer Center Invited Speaker: Roger Stupp – Northwestern University Feinberg School of Medicine Invited Speaker: Martin van den Bent – Erasmus University Medical Center Invited Speaker: Vinai Gondi – Northwestern Medical Cancer Center

Request A Quotation!

Feasibility Trial of Optune for Children With Recurrent or

Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma start a conversation Overview Conditions: malignant glioma ependymoma Treatment: optune system (novottf-200a system tumor treating fields ttfields) Sponsor: Pediatric Brain Tumor Consortium Collaborator: National Cancer Institute (NCI) Start date: January 2017 End date

Request A Quotation!

Optune Delivered Electric Field Therapy in Treating

This clinical trial studies the side effects and how well Optune delivered electric field therapy works in treating children with high-grade glioma or supratentorial ependymoma that has come back is getting worse or does not respond to treatment

Request A Quotation!

Open Phase 1 and 2 Cancer Clinical Trials

Our experts play an active role in innovative and prestigious clinical trials to advance the science of pediatric cancer care We offer your child access to novel cancer clinical trials some of which are only available at Children's National

Request A Quotation!

New Hampshire Stem Cells

(Abstract #: QOLP-24) Patients/parents experiences of receiving Optune delivered tumor treatment fields: A Pediatric Brain Tumor Consortium Study: PBTC-048 J Lai 7:50 to 7:54 p m MST Nov 22 (Abstract #: RDNA-10) TTFields treatment planning for targeting multiple lesions spread throughout the brain Z Bomzon 7:30 to 9:30 p m MST Nov 22

Request A Quotation!

Adult Stem Cells – Page 17 – Stem Cell Clinic

SUZHOU China Nov 19 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone or the Company HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib (TIBSOVO) in China

Request A Quotation!

Feasibility Trial of Optune for Children With Recurrent or

PBTC-048 5UM1CA081457 ( U S NIH Grant/Contract ) First Posted: January 27 2017 Key Record Dates: Last Update Posted: September 24 2019 Last Verified: September 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Additional relevant MeSH terms: Layout table for MeSH terms Glioma Ependymoma Neoplasms Neuroepithelial Neuroectodermal Tumors

Request A Quotation!

Feasibility Trial of Optune for Children with Recurrent or

NCI Protocol #: PBTC-048 1 Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis under current treatment regimens For children with high-grade gliomas (HGG) once progression occurs most patients cannot be cured and median survival

Request A Quotation!

PDF MPro

Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference Roger J Packer Antonio Iavarone David T W Jones Jaishri O Blakeley Eric Bouffet Michael J Fisher Eugene Hwang Cynthia Hawkins Lindsay Kilburn Tobey MacDonald Stefan M Pfister Brian Rood Fausto J Rodriguez Uri Tabori Vijay Ramaswamy Yuan Zhu Jason Fangusaro

Request A Quotation!

PDF MPro

Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference Roger J Packer Antonio Iavarone David T W Jones Jaishri O Blakeley Eric Bouffet Michael J Fisher Eugene Hwang Cynthia Hawkins Lindsay Kilburn Tobey MacDonald Stefan M Pfister Brian Rood Fausto J Rodriguez Uri Tabori Vijay Ramaswamy Yuan Zhu Jason Fangusaro

Request A Quotation!

Novocure Announces 43 Presentations on Tumor Treating

Presentations on Tumor Treating Fields cover a broad and growing range of topics with nearly 80 percent of presentations prepared by external authors ST HELIER Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields including three oral presentations will be featured at the 24th Annual Meeting of the Society for Neuro

Request A Quotation!

Neurology Neurological Sciences Clinical Trials

PBTC-048 Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma PBTC-049 A Phase I Study of Savolitinib in Recurrent Progressive or Refractory Primary CNS Tumors PBTC-050

Request A Quotation!

Novocure Announces 43 Presentations on Tumor Treating

Presentations on Tumor Treating Fields cover a broad and growing range of topics with nearly 80 percent of presentations prepared by external authors ST HELIER Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields including three oral presentations will be featured at the 24th Annual Meeting of the Society for Neuro

Request A Quotation!

Novocure Announces 43 Presentations on Tumor Treating

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields including three oral presentations will be featured at the 24 th Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov 20 through Nov 24 in Phoenix Presentations on Tumor Treating Fields cover a broad and growing range of topics

Request A Quotation!

Mamba Pen Blanks

SKU: PBTC-048 Category: Color Swirl Description Additional information Reviews (0) Green Blue and Charcoal Color Swirl Each blank is unique but the colors remain constant due to the extensive testing and documentation of specific color recipes Standard pen blank sizes are 5″ x 3/4″ x 3/4″ and prices are per blank The Alumilite Advantage! Alumilite is by far the best resin I

Request A Quotation!

Pediatric Neuro

PBTC-048 Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma PBTC-049 A Phase I Study of Savolitinib in Recurrent Progressive or Refractory Primary CNS Tumors PBTC-050 A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors PBTC-051 Phase I

Request A Quotation!

PBTC

PBTC-048 Imaging Protocol Standard MR imaging will include Sagittal T1 MPRAGE axial T2 FLAIR axial T2 post gadolinium sagittal 3D T1 (with reconstructions) and post gadolinium axial T1 images 3 Tesla MRI protocol: Sagittal T1 MPRAGE (slice thickness 1 0mm skip 0 25 cm FOV mode 3D) TR=2100ms TE=min flip angle 7-15 degrees Axial T2 images (slice thickness 2mm skip 0 20 cm

Request A Quotation!

Full Schedule

Moderator: Glenn J Lesser – Wake Forest Baptist Medical Center Moderator: W K Alfred Yung – University of Texas MD Anderson Cancer Center Invited Speaker: Roger Stupp – Northwestern University Feinberg School of Medicine Invited Speaker: Martin van den Bent – Erasmus University Medical Center Invited Speaker: Vinai Gondi – Northwestern Medical Cancer Center

Request A Quotation!
Copyright © 2014. All rights reserved.
^ Back to Top